Expert Adviser:

Amber is near completion of her Ph.D. in Cell and Developmental Biology at Oregon Health & Science University. During graduate school, she worked in business development and studied biomedical technology commercialization. Her combined passion for science and strategic planning provides her Mesothelioma clients with important insights for drug development.  More

MPNs Oncology Resources

Medical Conference Coverage:

Analysts cover major Mesothelioma Conferences and deliver expert analysis of noteworthy scientific, clinical, and commercial changes. The unmet need for effective treatment of mesothelioma is high, with 5-year survival of only ~10% overall. Novel agents are emerging with promising efficacy and the treatment landscape is likely to evolve dramatically over the next 3-5 years.   More

Competitive Landscape Analysis:

Chemotherapy remains the backbone of treatment for mesothelioma, but outcomes remain dismal and novel approaches are desperately needed. Innovative approaches including targeted therapies, immunotherapies, and antibody-drug conjugates showing promise are addressed. Quarterly coverage delivers profiles across the entire competitive landscape, providing valuable analytics of drugs in all phases of development.   More

Monthly Surveillance Reports:

ONCrg Sentinel provides vigilant monitoring of rapidly evolving scientific, clinical, and commercial activities in mesothelioma. ONCrg experts deliver incisive commentaries on current news events to inform subscribers each month, preparing them to respond wisely to ever-changing market conditions.   More